Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 32-37

  Moller, Robert A ^a,c   Fisher, Jeannine M ^b   Taylor, Ann E ^b   Kolluri, Sheela ^b   Gardner, Mark J ^b   Obach, R Scott ^c   Walsky, Robert L ^c  

^a Pfizer Worldwide Clinical Development   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER INC   (United States)

Author keywords

Chlorzoxazone; CYP2D6; CYP2E1; Dextromethorphan; Lasofoxifene

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DEXTROMETHORPHAN; DEXTRORPHAN; GUAIFENESIN; LASOFOXIFENE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; FEMALE; HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STEADY STATE;

ADMINISTRATION, ORAL; CHLORZOXAZONE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; DEXTROMETHORPHAN; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPEPSIA; FEMALE; HUMANS; INPATIENTS; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTMENOPAUSE; PYRROLIDINES; RETROSPECTIVE STUDIES; TETRAHYDRONAPHTHALENES; TIME FACTORS;

EID: 32344443131     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G347     Document Type: Article

References (15)

1. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
3. Morello KC, Wurz GT, DeGregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol 2002;43:63-76.
4. Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 2001;61:8683-8.
5. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068-76.
6. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005.
7. Bolognese M, Moffett A, Lee A. Lasofoxifene is superior to raloxifene in the prevention of bone loss in postmenopausal women: 1-year results (abstract). Bone 2003;32(suppl 5):S93.
8. Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol 2002;53:155-62.
9. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001-6.
10. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647-60.
11. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Mineral Metab 1996;14:1-9.
12. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991;14(suppl 2):S5-14.
13. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 1999;85:23-9.
14. Rosati RL, Silva Jardine P, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998;41:2928-31.
15. Moller R, Fisher J, Taylor A. The effects of lasofoxifene on the single dose pharmacokinetics of chlorzoxazone and dextromethorphan in post-menopausal women (abstract R6215). AAPSJ 2004;6.